Child Development and Exercise Center, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, the Netherlands.
Phys Ther. 2022 Oct 6;102(10). doi: 10.1093/ptj/pzac099.
The purpose of this study was to critically appraise and summarize the evidence for reliability of muscle strength and muscle power assessment in patients with neuromuscular diseases (NMDs) using isokinetic dynamometry.
PubMed, CINAHL, and Embase electronic databases were searched from inception to March 8, 2022. Studies designed to evaluate reliability of muscle strength and power measurements using isokinetic dynamometry were included in this review. First, the methodological quality of the studies was assessed according to the Consensus-Based Standards for the Selection of Health Measurement Instruments guidelines. Next, the quality of measurement properties was determined. Finally, the methodological quality and quality of measurement properties of the studies were combined to obtain a best-evidence synthesis.
A best-evidence synthesis of reliability was performed in 11 studies including postpoliomyelitis syndrome (n = 5), hereditary motor and sensory neuropathy (n = 2), motor neuron diseases (n = 1), myotonic dystrophy (n = 1), and groups of pooled NMDs (n = 2). A best-evidence synthesis on measurement error could not be performed. Quality of evidence on reliability ranged from high in postpoliomyelitis syndrome to very low in hereditary motor and sensory neuropathy, motor neuron diseases, and groups of pooled NMDs. The most frequently used outcome measure was peak torque, which was reliable in all populations (intraclass correlation coefficient >0.7).
The quality of evidence for reliability of isokinetic dynamometry was found to vary substantially among different NMDs. High quality of evidence has been obtained only in patients with postpoliomyelitis syndrome. Further research is needed in the majority of known NMDs to determine reliability and validity of isokinetic dynamometry.
The ability of isokinetic dynamometers to capture clinically relevant changes in muscle strength and muscle power in NMDs remains unclear. Isokinetic dynamometry results in NMDs should be interpreted with caution.
本研究旨在通过等速测力法对神经肌肉疾病(NMDs)患者肌肉力量和肌肉功率评估的可靠性进行批判性评价和总结。
从建库到 2022 年 3 月 8 日,检索了 PubMed、CINAHL 和 Embase 电子数据库。本综述纳入了旨在评估使用等速测力法评估肌肉力量和功率测量可靠性的研究。首先,根据共识基础健康测量仪器选择标准评估研究的方法学质量。其次,确定测量特性的质量。最后,将研究的方法学质量和测量特性质量结合起来,得出最佳证据综合。
11 项研究进行了可靠性最佳证据综合,包括脊髓灰质炎后综合征(n=5)、遗传性运动感觉神经病(n=2)、运动神经元病(n=1)、肌强直性营养不良(n=1)以及混合 NMD 组(n=2)。无法进行测量误差的最佳证据综合。可靠性的证据质量从脊髓灰质炎后综合征的高到遗传性运动感觉神经病、运动神经元病和混合 NMD 组的极低不等。最常使用的结果测量指标是峰值扭矩,在所有人群中均具有可靠性(组内相关系数>0.7)。
不同 NMDs 中等速测力法可靠性的证据质量差异很大。仅在脊髓灰质炎后综合征患者中获得了高质量的证据。需要对大多数已知的 NMD 进行进一步研究,以确定等速测力法的可靠性和有效性。
等速测力计捕捉 NMDs 中肌肉力量和肌肉功率的临床相关变化的能力仍不清楚。在 NMDs 中,应谨慎解释等速测力法的结果。